匹多莫德联合氨溴特罗治疗小儿急性支气管炎的临床研究

Clinical study of pidotimod combined with ambroxol in the treatment of acute bronchitis in children

目的对急性支气管炎患儿接受匹多莫德+氨溴特罗治疗的临床价值进行系统研究,以尽快改善患儿临床症状。方法选择我院2017年09月-2019年09月收治的50例急性支气管炎患儿作为实验对象,随机数字表法分组后探究每组治疗效果。对照组(25例):应用氨溴特罗治疗;实验组(25例):应用匹多莫德+氨溴特罗治疗。对比两组患儿临床症状消失时间、IgG指标、IgM指标、IgA指标。结果实验组肺部啰音消失时间为(5.21±1.16)d、咳嗽消失时间为(3.44±1.16)d,两项指标数值均比对照组低,临床比较差异性显著(P<0.05);实验组IgG指标为(7.89±1.45)g/L、IgM指标为(1.45±0.33)g/L、IgA指标为(1.36±0.51)g/L,均比对照组高,差异具备统计学研究意义(P<0.05)。结论将匹多莫德+氨溴特罗治疗方式应用于急性支气管炎患儿临床治疗中,能够使患儿的病状体征得到明显改善,疗效确切。

Objective To study the clinical value of the treatment of acute bronchitis with Mowder+Ambroxol in order to improve the clinical symptoms of children.Methods 50 children with acute bronchitis in our hospital from September 2017 to September 2019 were selected as the experimental subjects.The Control Group(25 cases)was treated with Ambroxol,and the experimental group(25 cases)was treated with Mowder and Ambroxol.The clinical symptom disappeared time,IgG Index,IgM Index and IgA index were compared between the two groups.Results The disappearance time of Lung Rales in experimental group was(5.21±1.16)d、Disappearance time of cough(3.44±1.16)d.The values of the two indexes were lower than those of the control group,and the clinical differences were significant(P<0.05)IGG,IGM and IGA in the experimental group were(7.89±1.45)g/l,(1.45±0.33)g/l and(1.36±0.51)g/l respectively,which were significantly higher than those in the Control Group(P<0.05).Conclusion The use of MOWDER+Ambroxol in the treatment of children with acute bronchitis can significantly improve the symptoms and signs of children with definite efficacy.